New antibody therapy shows promise for rare amyloidosis
NCT ID NCT07151690
First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 4 times
Summary
This phase 2 trial is testing a drug called CM336 in 21 people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. CM336 is a bispecific antibody that helps the immune system target and destroy the cells making these proteins. The study aims to see if the drug can improve blood markers and organ function, while monitoring for side effects like cytokine release syndrome.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CM336 (a bispecific antibody that targets BCMA and CD3 proteins to help the immune system attack amyloid-producing cells)
- What this could lead to
- If successful, this could offer a new, less intensive treatment option for people newly diagnosed with AL amyloidosis, potentially improving blood and organ function without the need for long-term medication.
- What could go wrong
- This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The drug can cause serious side effects like cytokine release syndrome (CRS) and nerve problems, and it may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LIGHT CHAIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITINGTianjin, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.